Navigation Links
Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year
Date:2/27/2008

FREDERICK, Md., Feb. 27 /PRNewswire/ -- Vaccinogen, Inc. announced that its new vaccine to block colon cancer from recurring will be commercially available in Europe starting June 2008.

"This makes OncoVAX(R) the world's first commercially viable vaccine for colon cancer," said Dr. Michael G. Hanna, Jr., Ph.D., Chairman & CEO of Vaccinogen. "It is the beginning of our worldwide strategy of profitable distribution. Questions of the feasibility of patient specific anti-cancer therapies have been raised and this new European initiative will obviate these issues."

Pro Vaccine AG, a leading Swiss-based pharmaceutical distributor, will begin distributing OncoVAX(R) throughout Switzerland starting with Zurich and Neuchatel by June 2008. "We are very excited about the prospects of offering OncoVAX(R) to Swiss and foreign patients," said Renato Duckeck, GM of Pro Vaccine.

Pharmacenter Hungary, a rapidly growing oncology company that commercializes a broad portfolio of oncology treatments, will begin distributing the vaccine in Hungary, Czech Republic, Slovakia, Poland, Romania, Bulgaria and Slovenia starting in the third quarter of 2008. Dr. Christian Galli, Director of Business Development of Pharmacenter Hungary noted, "We recognize the excellent opportunity OncoVAX(R) provides us and the growing population of colon cancer patients in Eastern Europe."

About OncoVAX(R)

OncoVAX(R) immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.

Vaccinogen's scientists prepare a vaccine from the patient's own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth "booster" is administered six months later. OncoVAX(R) reduces recurrence and deaths by over 50%.

About Vaccinogen

Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products -- Turning Cancer on Itself(TM). Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti- inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX(R) vaccines.
http://www.vaccinogeninc.com

Contact:

Andrew L. Tussing

Vaccinogen

atussing@vaccinogeninc.com

301-668-8400


'/>"/>
SOURCE Vaccinogen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
2. Egenix Licenses Harvard Anti-Cancer Platform
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Modifying an anti-cancer drug makes it more specific
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
7. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
8. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
9. Combination vaccine protects monkeys from ebola and Marburg viruses
10. Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks
11. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s New ... San Francisco. Located at booth number 7301, representatives from the Thai Government, research ... the Thai biotechnology and life sciences sector. , Deputy Secretary General of ...
(Date:5/25/2016)... Md. (PRWEB) , ... May 25, 2016 , ... ... request for information (RFI) issued by the Office of the National Coordinator for ... patient experience, and determines if clinically relevant data were available when and where ...
(Date:5/25/2016)... Melbourne, FL (PRWEB) , ... May 25, 2016 , ... ... of eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah ... , a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ... with artificial intelligence, real-time decision support tools in the emergency ... at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology ... the David Intercontinental Hotel in Tel Aviv, Israel ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation ... and Border Protection (CBP) is testing its biometric identity ... San Diego to help identify certain non-U.S. citizens ... . The test, designed to help determine the efficiency and ... began in February and will run until May 2016. ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
Breaking Biology News(10 mins):